Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative

Reuters

09/24

Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative

**Daré Bioscience Awarded Up to $499,000 Grant from Gates Foundation to Support Global Preeclampsia Research** SAN DIEGO, Sept. 24, 2025 - Daré Bioscience Inc. (NASDAQ: DARE) announced today it has been awarded up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for global research projects targeting preeclampsia, a serious and underserved pregnancy complication. The funding is part of the Gates Foundation's Grand Challenges initiative and will benefit multiple organizations conducting pre-clinical research focused on the prevention, diagnosis, and treatment of preeclampsia worldwide. Daré's role will include strategic mentorship and technical guidance to grantee organizations, aiming to advance innovative solutions for a condition that remains a leading cause of maternal and infant mortality, and for which no FDA-approved treatments currently exist.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534154-en) on September 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569706251"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569706251\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569706251?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569706251","market":"fut","top_or_hot":-1,"title":"Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Daré Bioscience Awarded Up to $499,000 Grant from Gates Foundation to Support Global Preeclampsia Research** SAN DIEGO, Sept. 24, 2025 - Daré Bioscience Inc. (NASDAQ: DARE) announced today it has been awarded up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for global research projects targeting preeclampsia, a serious and underserved pregnancy complication. The funding is part of the Gates Foundation's Grand Challenges initiative and will benefit multiple organizations conducting pre-clinical research focused on the prevention, diagnosis, and treatment of preeclampsia worldwide. Daré's role will include strategic mentorship and technical guidance to grantee organizations, aiming to advance innovative solutions for a condition that remains a leading cause of maternal and infant mortality, and for which no FDA-approved treatments currently exist.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534154-en) on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-24 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Daré Bioscience Awarded Up to $499,000 Grant from Gates Foundation to Support Global Preeclampsia Research** SAN DIEGO, Sept. 24, 2025 - Daré Bioscience Inc. (NASDAQ: DARE) announced today it has been awarded up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for global research projects targeting preeclampsia, a serious and underserved pregnancy complication. The funding is part of the Gates Foundation's Grand Challenges initiative and will benefit multiple organizations conducting pre-clinical research focused on the prevention, diagnosis, and treatment of preeclampsia worldwide. Daré's role will include strategic mentorship and technical guidance to grantee organizations, aiming to advance innovative solutions for a condition that remains a leading cause of maternal and infant mortality, and for which no FDA-approved treatments currently exist.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534154-en) on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL2TpW3:1","article_id":"2569706251","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569706251","pubTimestamp":1758715216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire  on September 24, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","DARE":"Dare Bioscience","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4584":"避孕概念","BK4007":"制药","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"DaréBioscience获得盖茨基金会高达499,000美元的资助，以支持全球先兆子痫研究；将指导大挑战计划下的多个组织","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"DARE":0.9},"content_text":"Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative\n    \n\n        **Daré Bioscience Awarded Up to $499,000 Grant from Gates Foundation to Support Global Preeclampsia Research** SAN DIEGO, Sept. 24, 2025 - Daré Bioscience Inc. (NASDAQ: DARE) announced today it has been awarded up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for global research projects targeting preeclampsia, a serious and underserved pregnancy complication. The funding is part of the Gates Foundation's Grand Challenges initiative and will benefit multiple organizations conducting pre-clinical research focused on the prevention, diagnosis, and treatment of preeclampsia worldwide. Daré's role will include strategic mentorship and technical guidance to grantee organizations, aiming to advance innovative solutions for a condition that remains a leading cause of maternal and infant mortality, and for which no FDA-approved treatments currently exist.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534154-en) on September 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}